Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis

Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP). It is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.

NCT Number	NCT06447441
Lead Sponsor	Chimei Medical Center Collaborators: E-DA Hospital
Conditions	Critically Ill, Sepsis, Mortality Rate, Critical Care
Enrollment	240 participants
Start Date	2024-07-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-06-17